World's First Gene Therapy During Heart Bypass Surgery Targets Vessel Longevity in Scotland
核心洞察
A 73-year-old man in Scotland became the world's first patient to receive gene therapy during heart bypass surgery, marking a breakthrough in cardiovascular treatment.
The PROTECT trial delivers TIMP-3 gene therapy (搜索) directly to vein grafts during surgery to prevent vessel thickening and blockages that commonly cause bypass failure.
The innovative ex vivo treatment approach uses viral vectors to strengthen grafted vessels before implantation, potentially extending bypass durability beyond current standards.
A 73-year-old man at Scotland's Golden Jubilee University National Hospital has become the world's first patient to receive gene therapy during heart bypass surgery, marking a significant milestone in cardiovascular medicine. The groundbreaking procedure combines traditional bypass surgery with experimental gene therapy designed to extend the lifespan of grafted blood vessels.
Revolutionary Approach to Bypass Longevity
The innovative treatment addresses a fundamental limitation of heart bypass surgery: vein grafts frequently fail because they cannot withstand the high pressure of the heart's arterial system. Once connected to the heart, veins taken from the leg must endure much higher pressure than they were designed for, leading to shrinkage, reduced blood flow, and eventual loss of function over time.
"Our team has developed a new approach to prevent vein graft failure. The new gene therapy has been developed over more than two decades of teamwork involving many experts," said Professor Colin Berry from the University of Glasgow, NHS Glasgow and Greater Clyde, and NHS Golden Jubilee (搜索).
TIMP-3 Gene Therapy Mechanism
The treatment involves delivering the TIMP-3 (搜索) (Tissue Inhibitor of Metalloproteinases (搜索)-3) gene into vein grafts using a viral vector. TIMP-3 is a protein that regulates tissue remodeling and controls metalloproteinase activity—enzymes that contribute to vascular wall thickening and degeneration.
The therapy is administered ex vivo, meaning the vein is treated outside the body immediately after removal from the patient's leg and before implantation. This timing allows for safe and efficient gene delivery directly to the graft tissue. The mechanism induces increased TIMP-3 (搜索) protein production in the graft to counteract processes that lead to vessel narrowing and occlusion.
The PROTECT Trial Framework
The PROTECT study represents the culmination of more than 20 years of translational research into TIMP-3 (搜索)'s role in vascular remodeling. The trial is led by NHS Greater Glasgow and Clyde and the University of Glasgow in collaboration with NHS Golden Jubilee (搜索) and the University of Edinburgh.
"I'm hugely grateful to the Medical Research Council and British Heart Foundation for helping the team translate this laboratory discovery to clinical evaluation," commented Professor Andrew Baker, Academic Lead for the study at the University of Edinburgh and Visiting Professor at the University of Glasgow.
The trial has received support from the Medical Research Council and the British Heart Foundation, with backing from national infrastructure dedicated to advanced therapies, including the Cell and Gene Therapy Catapult and several university programs.
Clinical Significance and Future Implications
This intervention opens new possibilities for gene therapy applications in cardiovascular medicine, a field that currently has no approved gene therapies. Previous strategies such as therapeutic angiogenesis developed to improve heart perfusion have not achieved expected clinical results.
Professor James Leiper, Director of Research at the British Heart Foundation, noted: "This pioneering study is an inspiring reminder of how far gene therapy, which was once a distant scientific ambition, has come. Research funding from the BHF to Professor Andrew Baker over many years laid the groundwork for this study, generating the knowledge, experience, and proof-of-concept data needed to move this research out of the lab and into the clinic."
Current Treatment Landscape
Heart bypass surgery remains a life-saving treatment for patients with coronary heart disease (搜索), using healthy blood vessels to bypass narrowed or blocked arteries. The procedure typically employs veins from the leg, particularly the great saphenous vein, because they are readily available and simple to implant.
However, graft failure represents a frequent complication that can lead to symptom recurrence, new hospitalizations, and in severe cases, additional operations. The gene therapy approach aims to make vessels more stable and resistant from the outset by modifying their biological behavior before heart implantation.
Looking Forward
While the trial is still in early stages and requires further confirmation to demonstrate safety and clinical efficacy, it represents an important innovation in cardiovascular treatment. The field is moving toward more targeted approaches, including genetic editing of cardiovascular risk genes like PCSK9 and correction of genetic cardiomyopathies (搜索).
Several studies on rare inherited heart diseases have entered or are entering clinical phases, with results expected within one to two years. If successful, this gene therapy approach could significantly influence treatment standards for heart disease patients globally, potentially extending healthy life expectancy and reducing the need for repeat surgeries.